Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective

Estimating the prevalence of and treatment patterns for juvenile onset recurrent respiratory papillomatosis in Australia pre-vaccination: a pilot study

Daniel Novakovic A , Alan T. L. Cheng B F , Daron H. Cope C and Julia M. L. Brotherton D E

A St Luke’s Roosevelt Hospital, 1000 10th Avenue, New York, NY 10019, USA.

B Department of Paediatric Otolaryngology, The Children’s Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia.

C Gosford Hospital, Holden Street, Gosford, NSW 2250, Australia.

D Registries, Victorian Cytology Service, PO Box 310, East Melbourne, Vic. 8002, Australia.

E National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead, Discipline of Paediatrics and Child Health, School of Public Health, University of Sydney, Sydney, NSW 2006, Australia.

F Corresponding author. Email:

Sexual Health 7(3) 253-261
Submitted: 10 December 2009  Accepted: 13 April 2010   Published: 19 August 2010


Background: Recurrent respiratory papillomatosis (RRP) causes serious morbidity. RRP in Australia may be eliminated in the near future following the implementation of a national vaccination program using a human papillomavirus (HPV) vaccine that protects against infection with HPV types 6 and 11, those responsible for RRP. Baseline data on RRP prevalence and disease burden in Australia are lacking. Methods: Three study methods were used to estimate the burden of juvenile onset RRP in Australia. We conducted a retrospective chart review of RRP cases treated at The Children’s Hospital at Westmead over 10 years, examined the coding of these cases, and then calculated and applied the positive predictive value of the codes to national data to estimate the prevalence of RRP in Australia. We also conducted an online survey of otolaryngologists in Australia who manage RRP. Results: Nineteen patients were treated at the hospital over 10 years, involving 359 admissions. We estimate that between 33 and 56 RRP cases aged <20 are being treated nationally per year (0.6–1.1 per 100 000 persons), with children 5–9 years having a higher estimated rate of 1.2–1.8 per 100 000. Among 39 otolaryngologists treating juvenile onset RRP, the majority (73%) treated RRP in a paediatric tertiary hospital, and used the microdebrider for ablation of lesions. Conclusions: Our estimates of RRP disease burden agree with international estimates. As a small number of clinicians treat RRP nationally, we believe that establishment of a national RRP register is both feasible and necessary to monitor the impact of vaccination.

Additional keywords: genital warts, HPV, juvenile onset recurrent respiratory papillomatosis, lesions, paediatrics.


[1]  Buchinsky FJ Donfack J Derkay CS Choi SS Conley SF Meyer III CM et al 2008 Age of child, more than HPV type, is associated with clinical course in recurrent respiratory papillomatosis. PLoS One 3 e2263 doi:10.1371/journal.pone.0002263

[2]  Wiatrak BJ Wiatrak DW Broker TR Lewis L 2004 Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114 (Suppl 104) 1 23 doi:10.1097/01.mlg.000148224.83491.0f

[3]  Reeves WC Ruparelia SS Swanson KI Derkay CS Marcus A Unger ER RRP Task Force 2003 National registry for juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 129 976 82 doi:10.1001/archotol.129.9.976

[4]  Lindeberg H Oster S Oxlund I Elbrond O 1986 Laryngeal papillomas: classification and course. Clin Otolaryngol Allied Sci 11 423 9 doi:10.1111/j.1365-2273.1986.tb00146.x

[5]  Johnson K Derkay C 2009 Palliative aspects of recurrent respiratory papillomatosis. Otolaryngol Clin North Am 42 57 70 doi:10.1016/j.otc.2008.09.007

[6]  Kashima HK Shah F Lyles A Glackin R Muhammad N Turner L et al 1992 A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 102 9 13 doi:10.1288/00005537-199201000-00002

[7]  Wiatrak BJ . Recurrent respiratory papillomatosis. In Graham JM, Scadding GK, Bull PD, editors. Pediatric ENT. Berlin: Springer-Verlag; 2007. pp. 256–65.

[8]  Cheng ATL Backer CL Holinger LD Dunham ME Mavroudis C Gonzalez-Crussi F 1997 Histopathologic changes after pericardial patch tracheoplasty. Arch Otolaryngol Head Neck Surg 123 1069 72

[9]  Maran A Amella CA DiLorenzo TP Auborn KJ Taichman LB Steinberg BM 1995 Human papillomavirus type 11 transcripts are present at low abundance in latently infected respiratory tissues. Virology 212 285 94

[10]  Derkay CS Wiatrak B 2008 Recurrent respiratory papillomatosis: a review. Laryngoscope 118 1236 47 doi:10.1097/MLG.0b013e31816a7135

[11]  Hawkes M Campisi P Zafar R Punthakee X Dupuis A Forte V et al 2008 Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatr Infect Dis J 27 149 54

[12]  Rady PL Schnadig VJ Weiss RL Hughes TK Tyring SK 1998 Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope 108 735 40

[13]  Gelinas JF Manoukian J Cote A 2008 Lung involvement in juvenile onset recurrent respiratory papillomatosis: a systematic review of the literature. Int J Pediatr Otorhinolaryngol 72 433 52 doi:10.1016/j.ijporl.2007.12.003

[14]  Stamataki S Nikolopoulos TP Korres S Felekis D Tzangaroulakis A Ferekidis E 2007 Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck 29 155 62 doi:10.1002/hed.20491

[15]  Derkay CS 2001 Recurrent respiratory papillomatosis. Laryngoscope 111 57 69 doi:10.1097/00005537-200101000-00011

[16]  Wu R Coniglio SJ Chan A Symons MH Steinberg BM 2007 Up-regulation of Rac1 by epidermal growth factor mediates COX-2 expression in recurrent respiratory papillomas. Mol Med 13 1 50 doi:10.2119/2007-00005.Wu

[17]  Zeitels SM Lopez-Guerra G Burns JA Lutch M Friedman AM Hillman RE 2009 Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol 118(Suppl 201) 1 24

[18]  Haleden C Majmudar B 1986 The relationship between juvenile laryngeal papillomatosis and maternal condylomata acuminata. J Reprod Med 318 804 7

[19]  Tenti P 1999 Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol 93 475 9

[20]  DeVoti JA Rosenthal DW Wu R Abramson AL Steinberg BM Bonagura VR 2008 Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis. Mol Med 14 1 17 doi:10.2119/2008-00060.DeVoti

[21]  Stern Y Felipovich A Cotton RT Segal K 2007 Immunocompetency in children with recurrent respiratory papillomatosis: prospective study. Ann Otol Rhinol Laryngol 116 169 71

[22]  Shah K Kashima H Polk BF Shah F Abbey H Abramson A et al 1986 Rarity of cesearean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 68 795 9

[23]  Garland SM Hernandez-Avila M Wheeler CM Perez G Harper DM Leodolter S et al 2007 Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356 1928 43

[24]  Schaffer A Brotherton J Booy R 2007 Do human papillomavirus vaccines have any role in newborns and the prevention of recurrent respiratory papillomatosis in children? J Paediatr Child Health 43 579 80 doi:10.1111/j.1440-1754.2007.01205.x

[25]  Matys K , Hood S , Bautista O , Esser M , Saah A . Maternal transfer of anti-HPV antibodies following vaccination with Gardasil. [conference abstract] P-03.51. Presented at the 25th International Papillomavirus Conference, Malmo, Sweden, 8–14 May, 2009.

[26]  Somers GR Tabrizi SN Borg AJ Garland SM Chow CW 1997 Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatr Pathol Lab Med 17 53 64 doi:10.1080/107710497175029

[27]  Benjamin B Parsons DS 1988 Recurrent respiratory papillomatosis: a 10 year study. J Laryngol Otol 102 1022 8 doi:10.1017/S0022215100107169

[28]  Gabbott M Cossart YE Kan A Konopka M Chan R Rose BR 1997 Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. J Clin Microbiol 35 3098 103

[29]  Schraff S Derkay CS Burke B Lawson L 2004 American Society of Pediatric Otolaryngology members’ experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg 130 1039 42

[30]  Australian Institute of Health and Welfare. Interactive national hospital data (datacubes). Available online at: [verified 7 June 2010].

[31]  Silverberg MJ Thorsen P Lindeberg H Ahdieh-Grant L Shah KV 2004 Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg 130 711 6 doi:10.1001/archotol.130.6.711

[32]  Australian Institute of Health and Welfare. Indigenous identification in hospital separations data-quality report. Health Services Series no.35. HSE 85. Canberra: AIHW; 2010.

[33]  Campisi P Canadian JORRP Working Group 2010 The epidemiology of juvenile onset recurrent respiratory papillomatosis derived from a population level national database. Laryngoscope 120 1233 45

[34]  Carvalho CM Huot L Charlois A-L Khalfallah SA Chapuis F Froehlich P 2009 Prognostic factors of recurrent respiratory papillomatosis from a registry of 72 patients. Acta Otolaryngol 129 462 70

[35]  Nunez DA 2009 A Update on human papilloma virus vaccination and the European recurrent respiratory papillomatosis registry. Clin Otolaryngol 34 12

[36]  He S Zurynski YA Elliott EJ 2009 Evaluation of a national resource to identify and study rare diseases: the Australian Paediatric Surveillance Unit. J Paediatr Child Health 45 498 504

[37]  Mouadeb DA Belafsky PC 2007 In-office laryngeal surgery with the 585 nm pulsed dye laser (PDL). Otolaryngol Head Neck Surg 137 477 81 doi:10.1016/j.otohns.2007.02.003

[38]  Rees CJ Postma GN Koufman JA 2007 Cost savings of unsedated office-based laser surgery for laryngeal papillomas. Ann Otol Rhinol Laryngol 116 45 8

Export Citation